Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment

Katharina Buerger, Stefan J. Teipel, Raymond Zinkowski, Trey Sunderland, Niels Andreasen, Kaj Blennow, Michael Ewers, John DeBernardis, Yong Shen, Daniel Kerkman, Yansheng Du, Harald Hampel

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We investigated the correlation between the apolipoprotein E ε4 allele (apoE ε4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau 231P) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau231P levels were significantly higher in apoE ε4 carriers compared to non-carriers (p < 0.001). Controlling for disease duration, the apoE ε4 effect on P-tau231P remained significant. Our study indicates that the apoE ε4 carrier status should be considered when CSF P-tau231P is evaluated as biomarker candidate of AD in MCI subjects.

Original languageEnglish
Pages (from-to)48-50
Number of pages3
JournalNeuroscience Letters
Volume391
Issue number1-2
DOIs
StatePublished - Dec 31 2005

Fingerprint

Apolipoprotein E4
Cerebrospinal Fluid
Alzheimer Disease
Alleles
tau Proteins
Threonine
Cognitive Dysfunction
Healthy Volunteers
Biomarkers

Keywords

  • Alzheimer's disease
  • Apolipoprotein E
  • Cerebrospinal fluid
  • Mild cognitive impairment
  • Phosphorylated tau protein
  • Risk factor

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Buerger, K., Teipel, S. J., Zinkowski, R., Sunderland, T., Andreasen, N., Blennow, K., ... Hampel, H. (2005). Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neuroscience Letters, 391(1-2), 48-50. https://doi.org/10.1016/j.neulet.2005.08.030

Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. / Buerger, Katharina; Teipel, Stefan J.; Zinkowski, Raymond; Sunderland, Trey; Andreasen, Niels; Blennow, Kaj; Ewers, Michael; DeBernardis, John; Shen, Yong; Kerkman, Daniel; Du, Yansheng; Hampel, Harald.

In: Neuroscience Letters, Vol. 391, No. 1-2, 31.12.2005, p. 48-50.

Research output: Contribution to journalArticle

Buerger, K, Teipel, SJ, Zinkowski, R, Sunderland, T, Andreasen, N, Blennow, K, Ewers, M, DeBernardis, J, Shen, Y, Kerkman, D, Du, Y & Hampel, H 2005, 'Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment', Neuroscience Letters, vol. 391, no. 1-2, pp. 48-50. https://doi.org/10.1016/j.neulet.2005.08.030
Buerger, Katharina ; Teipel, Stefan J. ; Zinkowski, Raymond ; Sunderland, Trey ; Andreasen, Niels ; Blennow, Kaj ; Ewers, Michael ; DeBernardis, John ; Shen, Yong ; Kerkman, Daniel ; Du, Yansheng ; Hampel, Harald. / Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. In: Neuroscience Letters. 2005 ; Vol. 391, No. 1-2. pp. 48-50.
@article{08294dd8ac2b46f793ae9cf664415ff4,
title = "Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment",
abstract = "We investigated the correlation between the apolipoprotein E ε4 allele (apoE ε4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau 231P) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau231P levels were significantly higher in apoE ε4 carriers compared to non-carriers (p < 0.001). Controlling for disease duration, the apoE ε4 effect on P-tau231P remained significant. Our study indicates that the apoE ε4 carrier status should be considered when CSF P-tau231P is evaluated as biomarker candidate of AD in MCI subjects.",
keywords = "Alzheimer's disease, Apolipoprotein E, Cerebrospinal fluid, Mild cognitive impairment, Phosphorylated tau protein, Risk factor",
author = "Katharina Buerger and Teipel, {Stefan J.} and Raymond Zinkowski and Trey Sunderland and Niels Andreasen and Kaj Blennow and Michael Ewers and John DeBernardis and Yong Shen and Daniel Kerkman and Yansheng Du and Harald Hampel",
year = "2005",
month = "12",
day = "31",
doi = "10.1016/j.neulet.2005.08.030",
language = "English",
volume = "391",
pages = "48--50",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment

AU - Buerger, Katharina

AU - Teipel, Stefan J.

AU - Zinkowski, Raymond

AU - Sunderland, Trey

AU - Andreasen, Niels

AU - Blennow, Kaj

AU - Ewers, Michael

AU - DeBernardis, John

AU - Shen, Yong

AU - Kerkman, Daniel

AU - Du, Yansheng

AU - Hampel, Harald

PY - 2005/12/31

Y1 - 2005/12/31

N2 - We investigated the correlation between the apolipoprotein E ε4 allele (apoE ε4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau 231P) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau231P levels were significantly higher in apoE ε4 carriers compared to non-carriers (p < 0.001). Controlling for disease duration, the apoE ε4 effect on P-tau231P remained significant. Our study indicates that the apoE ε4 carrier status should be considered when CSF P-tau231P is evaluated as biomarker candidate of AD in MCI subjects.

AB - We investigated the correlation between the apolipoprotein E ε4 allele (apoE ε4) carrier status, a major risk factor of Alzheimer's disease (AD), and levels of tau protein phosphorylated at threonine 231 (P-tau 231P) in cerebrospinal fluid (CSF) in predementia and clinical stages of AD and healthy controls (HC). Thirty-one subjects with mild cognitive impairment (MCI) who had converted to AD during follow-up were included, as well as 71 AD patients, and 29 HC subjects. In MCI, but not in AD and HC, CSF P-tau231P levels were significantly higher in apoE ε4 carriers compared to non-carriers (p < 0.001). Controlling for disease duration, the apoE ε4 effect on P-tau231P remained significant. Our study indicates that the apoE ε4 carrier status should be considered when CSF P-tau231P is evaluated as biomarker candidate of AD in MCI subjects.

KW - Alzheimer's disease

KW - Apolipoprotein E

KW - Cerebrospinal fluid

KW - Mild cognitive impairment

KW - Phosphorylated tau protein

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=27844561678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27844561678&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2005.08.030

DO - 10.1016/j.neulet.2005.08.030

M3 - Article

VL - 391

SP - 48

EP - 50

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1-2

ER -